 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: BETASERON (interferon beta-1b, Betaferon, Extavia) |
|
***************************************************** |
|
#Post#: 718-------------------------------------------------- |
|
(Abst.) Beta-interferon exposure and onset of SPMS |
|
By: agate Date: April 11, 2015, 7:23 pm |
|
--------------------------------------------------------- |
|
From PubMed, April 9, 2015: |
|
[quote]Eur J Neurol. 2015 Apr 6. |
|
Beta-interferon exposure and onset of secondary progressive |
|
multiple sclerosis |
|
Zhang T1, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, |
|
Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H; |
|
BC MS Clinic Neurologists. |
|
Author information |
|
1Division of Neurology and Brain Research Centre, Department of |
|
Medicine, University of British Columbia, Vancouver, BC, Canada. |
|
BACKGROUND AND PURPOSE: |
|
Beta-interferons (IFNβ) are the most widely prescribed |
|
drugs for patients with multiple sclerosis (MS). However, |
|
whether or not treatment with IFNβ can delay secondary |
|
progressive MS (SPMS) onset remains unknown. Our aim was to |
|
examine the association between IFNβ exposure and SPMS |
|
onset in patients with relapsing-remitting MS (RRMS). |
|
METHODS: |
|
A retrospective cohort study using British Columbia (Canada) |
|
population-based clinical and health administrative data |
|
(1985-2008) was conducted. RRMS patients treated with IFNβ |
|
(n = 794) were compared with untreated contemporary (n = 933) |
|
and historical (n = 837) controls. Cohort entry was the first |
|
clinic visit during which patients became eligible for IFNβ |
|
treatment (baseline). The outcome was time from baseline to SPMS |
|
onset. Cox regression models with IFNβ as a time-dependent |
|
exposure were adjusted for sex, and baseline age, disease |
|
duration, disability, *socioeconomic status and *comorbidities |
|
(*available for the contemporary cohorts only). Additional |
|
analyses included propensity score adjustment. |
|
RESULTS: |
|
The median follow-up for the IFNβ-treated, untreated |
|
contemporary and historical controls were 5.7, 3.7 and 7.3 |
|
years, and the proportions of patients reaching SPMS were 9.2%, |
|
11.8% and 32.9%, respectively. After adjustment for confounders, |
|
IFNβ exposure was not associated with the risk of reaching |
|
SPMS when either the contemporary or the historical untreated |
|
cohorts were considered (hazard ratio 1.07; 95% confidence |
|
interval 0.93-1.48, and hazard ratio 1.04; 95% confidence |
|
interval 0.74-1.46, respectively). Further adjustments and the |
|
propensity score yielded results consistent with the main |
|
analysis. |
|
CONCLUSIONS: |
|
Amongst patients with RRMS, use of IFNβ was not associated |
|
with a delayed onset of SPMS. |
|
[/quote] |
|
The abstract can be seen here |
|
http://www.ncbi.nlm.nih.gov/pubmed/25846809. |
|
***************************************************** |
